MAPK13

Across TCGA pan-cancer cohorts, MAPK13 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MAPK13’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MAPK13 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAPK13 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where MAPK13 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK13 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.570	<.001	10	view →
LUAD	Female	III,IV	+0.545	<.001	9	view →
COAD	Male	III,IV	+0.359	<.001	9	view →
PDAC	Female	All	−0.731	<.001	8	view →
HNSC	Male	IV	−0.527	<.001	8	view →
LSCC	Male	All	+0.283	<.001	8	view →
OV	All	All	+0.421	.029	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MAPK13–CCRCC

Open the CCRCC breakdown →